Event Calendar

Previous month Previous day Next day Next month
By Year By Month By Week Today Search Jump to month

 

Regional Symposium (University of Alabama)      
Friday, October 16, 2015 9:00 – 5:00      

Managing Patients with IPF: A Case-Based Symposium

Friday, October 16, 2015 
Clinician Session: 9:00 AM–12:15 PM
Patient Session: 1:15–5:00 PM

University of Alabama
 DoubleTree by Hilton Hotel Birmingham
808 South 20th Street
Birmingham, Alabama

register   register

Sponsored by The France Foundation and the Pulmonary Fibrosis Foundation.

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

CLINICIAN SESSION (9:00 AM–12:15 PM)
All education is case-based.

  • Diagnosis
  • Non-Pharmacologic Management
  • Pharmacologic Management
  • Disease Progression
  • Q&A/Panel Discussion

PATIENT SESSION (12:15–5:00 PM)

  • IPF Overview
  • Managing Symptoms
  • Comorbidities
  • Lung Transplantation
  • Local Resources/ILD Centers
  • New Therapies
  • Clinical Trial Participation

University of Alabama Faculty:
Joao de Andrade, MD (Chair)

Target Audience: This activity is intended for physicians, surgeons, critical care clinicians, advanced practice nurses, and other health care professionals involved in the diagnosis and management of patients with IPF, as well as patients with Pulomary Fibrosis and their caregivers.

Statement of Need: Two therapies were FDA approved in 2014 for patients with idiopathic pulmonary fibrosis (IPF). This milestone underlines the importance of accurate diagnosis of interstitial lung disease and presents clinicians with the opportunity to choose a treatment that matches patient characteristics. Case-based discussions are preferred by participants and this symposium offers learners an interactive format to diagnose several patients and to incorporate multiple approaches to managing a patient with IPF. A patient forum precedes the clinician symposium.

Educational Activity Learning Objectives 
Upon completion of this course, the participants should be able to:

  • Recognize the importance of early diagnosis of IPF in collaboration with an interdisciplinary team according to the 2011 ATS/ERS diagnostic criteria
  • Explain key facets of the 2011 ATS/ERS criteria that support accuarate, early, and definitive IPF diagnosis
  • Summarize the current understanding of the heterogeneity of the IPF disease process and strategies to monitor disease progression and treatment response
  • Describe the natural history and management of acute exacerbation of IPF
  • Describe the evidence contraindicating corticosteroids and NAC in IPF care
  • Discuss the efficacy, safety, and clinical application of new treatment options in patients with IPF
  • Formulate an education and disease management plan with patients that accounts for therapeutic options, patient preferences, and treatment goals
  • Describe common comorbidities of IPF and their mangement
  • Identify opportunities for referral to specialized care as part of the multidisciplinary IPF management plan


Accreditation/Designation Statements:
 This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Pulmonary Fibrosis Foundation and The France Foundation. The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation 
Physicians:
 The France Foundation designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure: The France Foundation and the Pulmonary Fibrosis Foundation adhere to ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education. Disclosure of the planning committee, content reviewers, and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

Resolution of Conflicts of Interest: In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation and the Pulmonary Fibrosis Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

Media Disclosure: Your registration, attendance at, and/or participation in this meeting constitutes consent to being photographed, videotaped, or recorded during the meeting by The France Foundation, its educational collaborators, or anyone authorized on behalf of these organizations. You further authorize, without any compensation paid to you, the use of any photographs, videos, or recordings that contain your likeness, image, or voice in any educational, informational, commercial, or promotional materials produced and/or distributed by The France Foundation, its educational collaborators, or anyone authorized by these organizations, as well as on any Internet sites maintained by any of these entities. Images/recordings used for these purposes will not be sold, and no personal information about you or the subject (other than event location and date) will be included in the production of any material.

The France Foundation fully complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant of this activity given by The France Foundation is in need of accommodation, please submit written requests via fax to 860-434-5390.

 

Event Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.


Venue Information:
Location:
Double Tree Birmingham
Street: 808 20th Street S
City: Birmingham
State: Alabama

ISO Start Time: 2015-10-16T09:00:00